Despite slim profits in the first months post-acquisition, the former Roxane Laboratories is expected to deliver a big sales boost to the global pharmaceutical company that acquired it, including next year's launch of a generic version of a drug that was among top 10 sellers in the world in 2013 and 2014.
Hikma Pharmaceuticals Plc saw operating profit for its generics unit drop to $8 million in the first half of 2016 from $33 million the same period last year, even though the unit's revenue tripled.…
Despite slim profits in the first months post-acquisition, the former Roxane Laboratories is expected to deliver a big sales boost to the global pharmaceutical company that acquired it, including next year's launch of a generic version of a drug that was among top 10 sellers in the world in 2013 and 2014.
Hikma Pharmaceuticals Plc saw operating profit for its generics unit drop to $8 million in the first half of 2016 from $33 million the same period last year, even though the unit's revenue tripled.…
